Eli Lilly Wins First Approval in China for Oral GLP-1 Weight-Loss Pill
China approved Eli Lilly’s orforglipron pill for weight loss, giving it an early lead over Novo Nordisk in the world’s second-largest drug market.
China approved Eli Lilly’s orforglipron pill for weight loss, giving it an early lead over Novo Nordisk in the world’s second-largest drug market.
Foundayo cut breathing interruptions by as much as 43.8% in a late-stage sleep apnea trial, supporting a new major market for Lilly.
Lilly partners with Hims & Hers so patients can access Zepbound ($299/mo) and Foundayo ($149/mo) at self-pay prices on the telehealth platform.
Strong Wegovy pill sales helped Novo Nordisk beat forecasts and lift its full-year 2026 sales and profit guidance for the third time.
Eli Lilly lifted its full-year revenue forecast to as much as $92 billion after strong Q3 sales of Mounjaro and Zepbound beat estimates, while trimming profit guidance on deal charges.
LUCENT-2 and VIVID-1 post-hoc data show Omvoh enabled comprehensive disease control and corticosteroid-free deep remission in IBD at one year.